Can a single gut bacterium rescue failing immunotherapy? F. prausnitzii strain EXL01 restores checkpoint-inhibitor response
Why IDO1 in inflamed TLS-positive lung tumors predicts immunotherapy response — and marks who might benefit from IDO1 inhibitors
How to screen for mature tertiary lymphoid structures in routine pathology — a standardized method validated across 357 tumors
Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy
Background Most cancer patients treated with anti-PD1 or anti-PDL1 immune checkpoint blockers do not derive clinical benefit. There is therefore a crucial need to identify reliable predictive biomarkers of response. Beyond PD1, several immune checkpoints, including CTLA4, LAG3, TIM3 and TIGIT, are associated with a T cell exhausted phenotype and play an important role in […]
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
How tertiary lymphoid structures predict pembrolizumab response in soft-tissue sarcoma — and why plasma cells matter
Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer
Background In the era of immuno-oncology, identifying primary resistance mechanisms to immune checkpoint inhibitors remains crucial. A better understanding of these mechanisms may help to identify novel pathways that can be targeted to improve response rates, as well as biomarkers that could support the selection of patients more likely to benefit from cancer immunotherapies. Among […]
Why intratumoral CD163+ macrophages predict anti-PD-1 resistance in non-small cell lung cancer
Which biliary tract cancers benefit from regorafenib–avelumab — and which biomarkers matter?
